Table 1.

Clinical variables of the cohort of 134 men undergoing prostate needle biopsy at two institutions in the United States

VariableInstitutions
All
Institution 1, BIDMCInstitution 2, UM
All patients94 (70%)40 (30%)134 (100%)
Age (y)65 (60-70)61 (54-70)64 (58-70)
Race*
    Caucasian78 (83%)35 (88%)113 (84%)
    Non-Caucasian16 (17%)5 (12%)21 (16%)
PSA (ng/mL)5.0 (4.0-7.0)5.8 (4.7-10.0)5.2 (4.0-8.0)
Prostate size by TRUS (cc)43 (31-57)43 (30-56)43 (30-57)
PSA density (ng/mL/cc)0.12 (0.08-0.19)0.13 (0.09-0.24)0.12 (0.08-0.19)
No. of cores taken12 (12)12 (12)12 (12)
    No. of cores involved2 (1-4)10 (1-12)2 (1-6)
    Cores involved (%)17 (8-33)77 (8-100)17 (8-50)
Prostate cancer diagnosis
    No17 (18)8 (20)25 (19)
    Yes77 (82)32 (80)109 (81)
Laterality
    Bilateral23 (24)23 (58)46 (34)
    Left25 (27)2 (5)27 (20)
    Right28 (30)1 (3)29 (22)
    Unknown1 (1)6 (16)7 (5)
    No cancer diagnosis17 (18)8 (20)25 (19)
Gleason score
    Gleason ≤627 (29)13 (33)40 (30)
    Gleason 739 (41)11 (28)50 (37)
    Gleason ≥88 (8)7 (18)15 (11)
    Not applicable or unknown20 (21)9 (23)29 (22)
  • Abbreviations: BIDMC, Beth Israel Deaconess Medical Center; UM, University of Michigan; TRUS, transrectal ultrasound.

  • * See Supplementary Table S1 for results on ethnicity by TMPRSS2-ERG fusion status among 100 patient's prostate cancer–positive biopsy cores.